(1) in subsection (a)(2)—

(2) in subsection (b)(2)—

(1) in the matter preceding subparagraph (A), by striking “and Indian Tribes—” and inserting “and Indian Tribes for the following purposes:”;

(2) by amending subparagraph (A) to read as follows:

(3) in subparagraph (B), by striking “for any” and inserting “For any”.

(1) a review of the activities carried out pursuant to sections 399H and 399I of the Public Health Service Act, as amended, to advance public education and awareness of fetal alcohol spectrum disorders (referred to in this section as “FASD”);

(2) a description of—

(3) an assessment of activities carried out pursuant to such sections 399H and 399I to support individuals with FASD.

(A) by striking “approved or cleared” each place it appears and inserting “approved, cleared, or otherwise legally marketed”; and

(B) by striking “opioid” each place it appears;

(A) by striking “approved or cleared” each place it appears and inserting “approved, cleared, or otherwise legally marketed”;

(B) in paragraph (1), by striking “opioid”;

(C) in paragraph (2)—

(D) in paragraph (3), by striking “opioid and heroin”; and

(1) by redesignating such part as part J; and

(2) by redesignating sections 581 through 584 as sections 596 through 596C, respectively.

(1) in the section heading, by striking “VIOLENCE RELATED STRESS” and inserting “TRAUMATIC EVENTS”;

(2) in subsection (a)—

(3) in subsection (b), by inserting “and dissemination” after “the development”;

(4) in subsection (d)—

(5) in subsection (e)—

(6) by amending subsection (h) to read as follows:

(7) by amending subsection (j) to read as follows:

(1) in paragraph (4), by striking “and” at the end;

(2) in paragraph (5), by striking the period at the end and inserting “; and”; and

(3) by adding at the end the following:

(1) by redesignating subsection (f) as subsection (g); and

(2) by inserting after subsection (e) the following:

(1) conduct and complete a study that evaluates cybersecurity risks and vulnerabilities associated with the 9–8–8 National Suicide Prevention Lifeline; and

(2) submit a report on the findings of such study to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives.

(1) in paragraph (3)(A)(i), by inserting “, which may include strategies to increase education and awareness of the potency and dangers of synthetic opioids (including drugs contaminated with fentanyl) and, as appropriate, other emerging drug use or misuse issues” before the semicolon; and

(2) in paragraph (4)(A), by inserting “and strategies to increase education and awareness of the potency and dangers of synthetic opioids (including drugs contaminated with fentanyl) and, as appropriate, emerging drug use or misuse issues” before the semicolon.

(1) by striking subsection (g) and inserting the following:

(2) by striking subsection (i) and inserting the following:

(1) recommended standards for effective at-home drug disposal systems to meet applicable requirements enforced by the Food and Drug Administration;

(2) recommended information to include as instructions for use to disseminate with at-home drug disposal systems;

(3) best practices and educational tools to support the use of an at-home drug disposal system, as appropriate; and

(4) recommended use of licensed health providers for the dissemination of education, instruction, and at-home drug disposal systems, as appropriate.

(1) an update on the actions taken by the FDA to consider the effectiveness, safety, benefit-risk profile, and use of approved opioid analgesic drugs;

(2) a timeline for an assessment of the potential need, as appropriate, for labeling changes, revised or additional postmarketing requirements, enforcement actions, or withdrawals for opioid analgesic drugs;

(3) an overview of the steps that the FDA has taken to support the development and approval of nonaddictive medical products intended to treat pain or addiction, and actions planned to further support the development and approval of such products; and

(4) an overview of the consideration by the FDA of clinical trial methodologies for analgesic drugs, including the enriched enrollment randomized withdrawal methodology, and the benefits and drawbacks associated with different trial methodologies for such drugs, incorporating any public input received under subsection (b).

(A) by inserting “a plan describing” after “will provide”; and

(B) by adding at the end the following: “Such plan may include a description of how such applicant will target outreach to women disproportionately impacted by maternal substance use disorder.”; and

(A) by redesignating subparagraph (CC) as subparagraph (DD); and

(B) by inserting after subparagraph (BB) the following:

(1) How States use funds for evidence-based treatments and services according to the standard of care for individuals with early serious mental illness and children with a serious emotional disturbance.

(2) The percentages of the State funding under the block grant program expended on early serious mental illness and first episode psychosis, and the number of individuals served under such funds.

(1) REPORT.—Not later than 180 days after the completion of the review under subsection (a), the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives a report describing—

(2) GUIDANCE.—Not later than 1 year after the date on which the report is submitted under paragraph (1), the Secretary shall update the guidance provided to States under the block grant program on coordinated specialty care and other evidence-based mental health care services for individuals with serious mental illness and children with a serious emotional disturbance, based on the findings and recommendations of such report.

(1) review the relevant data pertaining to the scheduling of products containing a combination of buprenorphine and naloxone that have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355); and

(2) if appropriate, request that the Attorney General initiate rulemaking proceedings to revise the schedules accordingly with respect to such products.

“(A) professional development of peer support specialists; and

“(B) making recovery support services available in nonclinical settings; and”;

“(d) Regional centers.—

(A) in the matter preceding subparagraph (A), by striking “and in such manner” and inserting “, in such manner, and containing such information and assurances, including relevant documentation,”; and

(B) in subparagraph (A), by striking “is capable of coordinating with other entities to carry out” and inserting “has the demonstrated capability to carry out, through referral or contractual arrangements”;

(A) by redesignating paragraphs (1) through (4) as subparagraphs (A) through (D), respectively, and adjusting the margins accordingly;

(B) by striking “With respect to” and inserting the following:

(C) by adding at the end the following:

(A) in subparagraph (A)—

(B) by amending subparagraph (E) to read as follows:

(C) by redesignating subparagraph (K) as subparagraph (L); and

(D) by inserting after subparagraph (J) the following:

(A) by striking “and abuse”; and

(B) by inserting “at increased risk for substance misuse” after “specific populations”;

(A) in the matter preceding subparagraph (A), by striking “Indian tribes” and inserting “Indian Tribes”;

(B) in subparagraph (A), by striking “and abuse”; and

(C) in subparagraph (B), by striking “peer mentoring” and inserting “peer-to-peer support”;

(A) in clause (iv), by striking “; and” and inserting a semicolon; and

(B) by adding at the end the following:

“(9) AUTHORIZATION OF APPROPRIATIONS.—To carry out this subsection, there are authorized to be appropriated—

(1) in the section heading, by inserting “; TREATMENT, RECOVERY, AND WORKFORCE SUPPORT GRANTS” after “CAREER ACT”;

(2) in subsection (b), by inserting “each” before “for a period”;

(3) in subsection (c)—

(4) in subsection (g)—

(5) in subsection (i)(2), by inserting “, which shall include employment and earnings outcomes described in subclauses (I) and (III) of section 116(b)(2)(A)(i) of the Workforce Innovation and Opportunity Act (29 U.S.C. 3141(b)(2)(A)(i)) with respect to the participation of such individuals with a substance use disorder in programs and activities funded by the grant under this section” after “subsection (g)”;

(6) in subsection (j)—

(7) in subsection (k), by striking “$5,000,000 for each of fiscal years 2019 through 2023” and inserting “$12,000,000 for each of fiscal years 2026 through 2030”.

(1) IN GENERAL.—Section 8071 of the SUPPORT for Patients and Communities Act (42 U.S.C. 5301 note; Public Law 115–271) is amended—

(2) CONFORMING AMENDMENT.—Subtitle F of title VIII of the SUPPORT for Patients and Communities Act (Public Law 115–271; 132 Stat. 4095) is amended by striking the subtitle heading and inserting the following: “Subtitle F—CAREER Act; Recovery Housing Pilot Program”.

(1) by striking the item relating to section 7183 and inserting the following:

“Sec. 7183. CAREER Act; treatment, recovery, and workforce support grants.”;

(2) by striking the item relating to subtitle F of title VIII and inserting the following:

(3) by striking the item relating to section 8071 and inserting the following:

“Sec. 8071. CAREER Act; Recovery Housing Pilot Program.”.

“(A) by injection or implantation for the purpose of maintenance or detoxification treatment; or

“(B) subject to a risk evaluation and mitigation strategy pursuant to section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) that includes elements to assure safe use of the drug described in subsection (f)(3)(E) of such section, including a requirement for post-administration monitoring by a health care provider;”.

(1) by redesignating the second subsection designated as subsection (l) as subsection (m); and

(2) in subsection (m)(1), as so redesignated—